AP NEWS

CareDx broadens HeartCare availability

September 17, 2018

BRISBANE, Calif., Sept. 17, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the launch of the Surveillance HeartCare® Outcomes Registry (SHORE).

CareDx will launch SHORE during the 22nd Annual Scientific Meeting of the Heart Failure Society of America (HFSA), September 15-18, 2018 in Nashville, TN. SHORE is a prospective, multi-center, observational, registry of patients receiving HeartCare surveillance. HeartCare provides information about heart transplant recipient immune activity and donor graft injury, including both AlloMap® (gene expression profiling) and AlloSure-Heart® (donor-derived cell-free DNA analysis).

“The marriage of gene expression profiling and dd-cfDNA promises additional insights as we continuously strive to improve the long-term care of our heart transplant patients,” says Shelley Hall, MD, FACC, FHFSA, FAST, Chief, Transplant Cardiology, MCS and Advanced Heart Failure at Baylor University Medical Center.

“HeartCare provides a comprehensive view into the health of the heart allograft, so we are seeing strong initial interest from transplant cardiologists to join SHORE,” said Jim Yee, MD, PhD, Chief Medical Officer, CareDx. “The design of SHORE is derived from the great experience with our previous OAR and D-OAR registries in heart transplantation which included 35 centers more than 2200 patients.”

HeartCare establishes a standardized routine surveillance schedule for heart transplant patients, and is broadly available today to centers across the United States.

About CareDx CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and AlloSure™ for post-transplant surveillance and Olerup SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA testing.

For more information, please visit: www.CareDx.com.

Forward Looking Statements

This press release contains forward-looking statements about our business, research, development and commercialization efforts, including statements regarding HeartCare and its potential benefits. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks associated with successful research, development and planned commercialization of our technologies, that are described in our filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed by us with the SEC on March 22, 2018 and the periodic reports that we have subsequently filed with the SEC. Any of these may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

CONTACTS:

CareDx, Inc.Sasha KingChief Commercial Officer415-287-2393sking@caredx.com

Investor RelationsDavid ClairIntegrated Corporate Relations, Inc.646-277-1266david.clair@icrinc.com

AP RADIO
Update hourly